• Cardiovascular disease is the largest cause of morbidity and a major cause of death in European countries.
• The Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) demonstrated that rosuvastatin 20 mg significantly reduced the incidence of major CVD events and all-cause mortality among individuals without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels 7 • Rosuvastatin is indicated in Europe for the prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event (having a Framingham risk >20 % or a SCORE risk >5 %), as an adjunct to correction of other risk factors
• Simvastatin is currently the most widely prescribed statin treatment in Sweden • The model assessed cost-effectiveness in the Swedish setting from a healthcare payer perspective
• CVD event rates were combined with epidemiological and unit cost data specific for the Swedish setting
Model Population
• Patients with a 10-year Framingham CVD risk >20 % were simulated in the model using the characteristics of the JUPITER clinical trial patients -JUPITER clinical trial patients:
Normal LDL-C levels (<3.4 mmol/L) hsCRP ( >2 mg/L)
% men
Mean age at entry of 66 years
Model Structure
• Initial and subsequent CVD events and death were estimated over the long term (20 years and lifetime of patients [to age 100 years])
• The model contains 3 health stages to simulate patients: 1) event free for the duration of the JUPITER trial, 2) event free beyond the 4 years of the trial for those without a CVD event, and 3) post−CVD event stage for those who experience a non-fatal CVD event (Figure 1) • For the Subsequent CVD Prevention stage, patients remain in this stage until they die or reach the specified timeframe (e.g., 20 years) -Patients who received rosuvastatin in the initial model stage continue on rosuvastatin when they enter this stage -Patients who received simvastatin in the initial stage continue on simvastatin when they enter this subsequent stage
Treatment efficacy
• Efficacy of R 10 mg, S 20 mg, and S 40 mg was estimated using the R 20 mg efficacy findings from the JUPITER trial and calibrated using the Framingham equation and the differences in the total cholesterol/high-density lipoprotein cholesterol ratio effects as observed in the STELLAR trial 12 Event probabilities for R 20 mg were calculated by dividing the JUPITER trial adjudicated quarterly event counts by the number of patients at risk at the beginning of a quarter for the first 4 years of the model Event probabilities per quarter for R 20 mg were used to construct survival curves for patients in the treatment and placebo groups. The survival curves were fitted to exponential curves and per-quarter event probabilities calculated
Relative risk of events with rosuvastatin 20 mg treatment was calculated by taking the ratio of treated and untreated event probabilities (estimated as 0.49) and calibrated to reflect treatment efficacy of comparator by using Framingham risk equation for CVD risk based on the differences in lipid effects between R 10 mg and 20 mg and S 20 mg and S 40 mg compared with R 20 mg
• The relative risk estimate was carried forward beyond the trial duration Assuming a 50 % smaller CVD event risk reduction than in the base case increased the ICER to 369,466 SEK (EUR 38,314), whereas assuming a 50 % greater risk reduction reduced the ICER to 87,788 SEK (EUR 9,104)
• Doubling the baseline risk reduced the ICER to 95,539 SEK (EUR 9,907), whereas reducing the risk by 50 % increased the ICER to 339,677 SEK (EUR 35,225) • The probabilistic sensitivity analysis ( Figure 5 ) indicated that at a willingness-topay of SEK 500,000 (EUR 51,850) per QALY gained, rosuvastatin 20 mg would be cost-effective in 80 % of the model replications
Conclusions
• Considering the generally accepted willingness-to-pay per QALY threshold value in Sweden, treatment with rosuvastatin 10 mg or 20 mg daily is a cost-effective treatment alternative to relevant doses of simvastatin in the primary prevention of CVD for Swedish patients with high baseline CV risk (10-year Framingham CVD risk >20 %)
• Model Assumptions
• Event risks were increased annually based on Framingham CHD risk age-adjusted calculations
• For the subsequent CVD prevention stage, age-based CVD event rates were taken from the statin trials meta-analysis developed for a NICE HTA 13 • Non-CVD death rates were calculated using data from Statistics Sweden • Costs and health outcomes were discounted by 3 % annually.
Utilities
• All patients were assigned an initial baseline age-dependent utility value -Decreased as the patient ages through the simulation
• Utility weights for each CVD event were based on estimates reported in the literature 13, 16 Results
• The following total CVD events were estimated to be avoided over the lifetime (per 100,000 patients): The cost-effectiveness of rosuvastatin versus simvastatin for the prevention of cardiovascular morbidity and mortality in patients with higher baseline risk -A Swedish economic evaluation based upon the JUPITER trial 
